Using a patented retroviral technique, we can produce mAbs faster, more cost effectively, with high yields, and with greater cell line stability than conventional production methods. Our exclusive process is also useful for developing mAbs to problematic peptides.

Check out our new products.

NeoClone in the news.

NeoClone is pleased to announce a licensing deal with Scarab Genomics to add high quality Shiga Toxin monoclonal antibodies to our catalog of antibody products. To learn more about Scarab Genomics click here.